Cargando…

Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells

Mutations in homologous recombination (HR) genes BRCA1 and BRCA2 predispose to tumorigenesis. HR-deficient cancers are hypersensitive to Poly (ADP ribose)-polymerase (PARP) inhibitors, but can acquire resistance and relapse. Mechanistic understanding how PARP inhibition induces cytotoxicity in HR-de...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schoonen, Pepijn M., Talens, Francien, Stok, Colin, Gogola, Ewa, Heijink, Anne Margriet, Bouwman, Peter, Foijer, Floris, Tarsounas, Madalena, Blatter, Sohvi, Jonkers, Jos, Rottenberg, Sven, van Vugt, Marcel A. T. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520019/ https://www.ncbi.nlm.nih.gov/pubmed/28714471 http://dx.doi.org/10.1038/ncomms15981

Ejemplares similares

Never tear us a-PARP: Dealing with DNA lesions during mitosis
por: Schoonen, Pepijn M., et al.
Publicado: (2017)

BRCA1 and CtIP promote alternative non-homologous end-joining at uncapped telomeres
por: Badie, Sophie, et al.
Publicado: (2015)

BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity
por: Heijink, Anne Margriet, et al.
Publicado: (2019)

Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition‐mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2‐deficient cancer cells
por: Schoonen, Pepijn M., et al.
Publicado: (2019)

Inflammatory signaling in genomically instable cancers
por: Talens, Francien, et al.
Publicado: (2019)

Interplay between Fanconi anemia and homologous recombination pathways in genome integrity
por: Michl, Johanna, et al.
Publicado: (2016)

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity
por: Becker, Jordan R., et al.
Publicado: (2018)

MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression
por: Rottenberg, Sven, et al.
Publicado: (2012)

TPX2/Aurora kinase A signaling as a potential therapeutic target in genomically unstable cancer cells
por: van Gijn, Stephanie E., et al.
Publicado: (2018)

BRCA2 Acts as RAD51 Loader to Facilitate Telomere Replication and Capping
por: Badie, Sophie, et al.
Publicado: (2010)

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells
por: Barazas, Marco, et al.
Publicado: (2018)

Functional genetic dropout screens and in vivo validation of candidate therapeutic targets using mouse mammary tumoroids
por: Paes Dias, Mariana, et al.
Publicado: (2022)

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
por: Reisländer, Timo, et al.
Publicado: (2019)

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
por: Francica, Paola, et al.
Publicado: (2018)

Trypanosoma cruzi PARP is enriched in the nucleolus and is present in a thread connecting nuclei during mitosis
por: Kevorkian, María Laura, et al.
Publicado: (2022)

Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model
por: Borst, Gerben R., et al.
Publicado: (2017)

Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model
por: Borst, Gerben R., et al.
Publicado: (2020)

PARP1 suppresses homologous recombination events in mice in vivo
por: Claybon, Alison, et al.
Publicado: (2010)

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations
por: von Werdt, Alexander, et al.
Publicado: (2021)

High Homology-Directed Repair Using Mitosis Phase and Nucleus Localizing Signal
por: Han, Jeong Pil, et al.
Publicado: (2020)

Processing DNA lesions during mitosis to prevent genomic instability
por: Audrey, Anastasia, et al.
Publicado: (2022)

Methylated-UHRF1 and PARP1 interaction is critical for homologous recombination
por: Hahm, Ja Young, et al.
Publicado: (2020)

WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
por: Burdova, Kamila, et al.
Publicado: (2019)

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
por: Bouwman, Peter, et al.
Publicado: (2010)

Rad51 and Dmc1 Form Mixed Complexes Associated with Mouse Meiotic Chromosome Cores and Synaptonemal Complexes
por: Tarsounas, Madalena, et al.
Publicado: (1999)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
por: Janysek, Dawn C., et al.
Publicado: (2021)

Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors
por: Xu, Junfen, et al.
Publicado: (2021)

PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
por: O’Sullivan Coyne, Geraldine, et al.
Publicado: (2022)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
por: Tacconi, Eliana MC, et al.
Publicado: (2019)

Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51
por: Manic, Gwenola, et al.
Publicado: (2021)

Restriction beyond the restriction point: mitogen requirement for G(2 )passage
por: Foijer, Floris, et al.
Publicado: (2006)

Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining
por: Beckta, Jason M., et al.
Publicado: (2015)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity
por: Tacconi, Eliana MC, et al.
Publicado: (2017)

PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
por: Sugimura, Kazuto, et al.
Publicado: (2008)

PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways
por: Beck, Carole, et al.
Publicado: (2014)

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
por: Lahiguera, Álvaro, et al.
Publicado: (2020)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
por: Zhang, Shaolu, et al.
Publicado: (2021)

Loss of CENP-I Impairs Homologous Recombination and Sensitizes Cells to PARP1 Inhibition
por: Dang, Tuyen T., et al.
Publicado: (2021)

Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?
por: Yin, Chao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tg7ffvc9fn7gk4bl82aomdcuna